NO983429D0 - Anvendelse av et texaphyrin til fremstilling av et medikament for anvendelse med et kjemoterapeutisk middel i kreftkjemosensitivisering - Google Patents

Anvendelse av et texaphyrin til fremstilling av et medikament for anvendelse med et kjemoterapeutisk middel i kreftkjemosensitivisering

Info

Publication number
NO983429D0
NO983429D0 NO983429A NO983429A NO983429D0 NO 983429 D0 NO983429 D0 NO 983429D0 NO 983429 A NO983429 A NO 983429A NO 983429 A NO983429 A NO 983429A NO 983429 D0 NO983429 D0 NO 983429D0
Authority
NO
Norway
Prior art keywords
texaphyrin
medicament
manufacture
chemotherapeutic agent
glycoprotein
Prior art date
Application number
NO983429A
Other languages
English (en)
Other versions
NO983429L (no
Inventor
Richard A Miller
Stuart W Young
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of NO983429D0 publication Critical patent/NO983429D0/no
Publication of NO983429L publication Critical patent/NO983429L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO983429A 1996-01-25 1998-07-24 Anvendelse av et texaphyrin til fremstilling av et medikament for anvendelse med et kjemoterapeutisk middel i kreftkjemosensitivisering NO983429L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/591,318 US5776925A (en) 1996-01-25 1996-01-25 Methods for cancer chemosensitization
PCT/US1997/000907 WO1997026915A1 (en) 1996-01-25 1997-01-23 Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization

Publications (2)

Publication Number Publication Date
NO983429D0 true NO983429D0 (no) 1998-07-24
NO983429L NO983429L (no) 1998-09-24

Family

ID=24366012

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983429A NO983429L (no) 1996-01-25 1998-07-24 Anvendelse av et texaphyrin til fremstilling av et medikament for anvendelse med et kjemoterapeutisk middel i kreftkjemosensitivisering

Country Status (14)

Country Link
US (1) US5776925A (no)
EP (1) EP0912196B9 (no)
JP (1) JP2000503989A (no)
KR (1) KR19990082024A (no)
CN (1) CN1093766C (no)
AT (1) ATE277637T1 (no)
AU (1) AU715025B2 (no)
DE (1) DE69730961T2 (no)
ES (1) ES2227671T3 (no)
HK (1) HK1018588A1 (no)
IL (1) IL125459A0 (no)
NO (1) NO983429L (no)
NZ (1) NZ331513A (no)
WO (1) WO1997026915A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US6200547B1 (en) * 1994-01-26 2001-03-13 Ferx Incorporated Magnetically responsive compositions for carrying biologically active substances and methods of production and use
US6482436B1 (en) 1993-01-29 2002-11-19 Ferx Incorporated Magnetically responsive composition
US5969111A (en) * 1994-04-14 1999-10-19 Board Of Regents, The University Of Texas System Texaphyrins substituted with imidazole are provided
RU2106146C1 (ru) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Средство для подавления опухолевого роста
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH10279502A (ja) * 1997-03-31 1998-10-20 Katsuro Tachibana 光感受性物質の励起方法
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
CA2370003C (en) 1999-01-13 2008-08-19 Tracey Brown A composition and method for the enhancement of the efficacy of drugs
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US7579338B2 (en) * 1999-10-29 2009-08-25 Pharmacyclics, Inc. Methods and compositions for treating atheroma, tumors and other neoplastic tissues
WO2001032210A2 (en) * 1999-10-29 2001-05-10 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
US20030031676A1 (en) * 1999-10-29 2003-02-13 Pharmacyclics, Inc. Conjugate compounds for treating atheroma and other diseases
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
WO2002017925A1 (en) * 2000-08-30 2002-03-07 Pharmacyclics, Inc. Non-symmetric tripyrrannes in the synthesis of novel macrocycles
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
JP2004513900A (ja) 2000-11-17 2004-05-13 ファーマサイクリクス,インコーポレイテッド テキサフィリン配位化合物およびその使用
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
WO2003039327A2 (en) 2001-11-02 2003-05-15 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
CN1615129A (zh) * 2001-12-13 2005-05-11 环状药物公司 影响神经病学进展的方法
US20030153493A1 (en) * 2001-12-13 2003-08-14 Pharmacyclics, Inc. Combination cancer therapy
WO2003072581A1 (en) 2002-02-26 2003-09-04 Board Of Regents, The University Of Texas System Cyclo[n]pyrroles and methods thereto
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
US20040010218A1 (en) * 2002-07-11 2004-01-15 Henderson Barbara W. Photodynamic therapy for the enhancement of vascular permeability to aid in drug delivery to diseased tissues
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
US7981928B2 (en) * 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
EP1765163A1 (en) * 2004-05-20 2007-03-28 Pharmacyclics, Inc. A method of enhancing visualization of atherosclerotic plaque
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
JP4972929B2 (ja) * 2005-03-25 2012-07-11 ニプロ株式会社 放射線増感剤
US20060217291A1 (en) * 2005-03-25 2006-09-28 Ichiro Hirotsu Radiosensitizer
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
JP5627181B2 (ja) * 2005-09-07 2014-11-19 アルケミア オンコロジー ピーティーワイ リミテッド ヒアルロナンおよび治療用抗体を含む治療用組成物ならびに治療方法
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
AU2007264361B2 (en) 2006-06-26 2013-07-18 The University Of British Columbia Secreted Protein Acidic and Rich in Cysteine (SPARC) as chemotherapeutic sensitizers
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
US20080279781A1 (en) * 2007-05-10 2008-11-13 Brookhaven Science Associates, Llc Glycosylated Carboranylporphyrins and Uses Thereof
TWI445696B (zh) 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的dna修復毒性
US9662328B2 (en) 2010-11-29 2017-05-30 National Yang-Ming University Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
BR112016029024A8 (pt) 2014-06-11 2021-07-20 Univ Texas composto, composição farmacêutica e uso
CA3047100A1 (en) * 2016-12-13 2018-06-21 Health Research, Inc. Near infrared (nir) photodynamic therapy (pdt) in combination with chemotherapy
WO2022036292A1 (en) 2020-08-14 2022-02-17 Board Of Regents, The University Of Texas System Texaphyrin derivatives for manganese chemotherapy, photoacoustic imaging, and photothermal therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins

Also Published As

Publication number Publication date
CN1213313A (zh) 1999-04-07
ES2227671T3 (es) 2005-04-01
HK1018588A1 (en) 1999-12-30
ATE277637T1 (de) 2004-10-15
DE69730961T2 (de) 2005-11-24
EP0912196A1 (en) 1999-05-06
AU715025B2 (en) 2000-01-13
JP2000503989A (ja) 2000-04-04
NO983429L (no) 1998-09-24
AU1833397A (en) 1997-08-20
WO1997026915A1 (en) 1997-07-31
NZ331513A (en) 2001-10-26
KR19990082024A (ko) 1999-11-15
US5776925A (en) 1998-07-07
CN1093766C (zh) 2002-11-06
EP0912196B1 (en) 2004-09-29
EP0912196B9 (en) 2005-01-05
IL125459A0 (en) 1999-03-12
DE69730961D1 (de) 2004-11-04

Similar Documents

Publication Publication Date Title
NO983429L (no) Anvendelse av et texaphyrin til fremstilling av et medikament for anvendelse med et kjemoterapeutisk middel i kreftkjemosensitivisering
GB9807639D0 (en) Anti-inflammatory agents
DK0623134T3 (da) Metalkomplekser af vandopløselige texaphyriner
MX368013B (es) Tratamiento de cáncer.
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
FI932032A (fi) Kinazolinderivat foer oekande av antitumoeraktivitet
NO932954L (no) 2,4-diaminokinazolin-derivater for aa oppnaa oeket antitumoraktivitet
ATE398464T1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
NO993654L (no) Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
NO20053947L (no) Forbedrede antitumorale behandlinger.
EP1359909A4 (en) CANCER THERAPY USING TRIPTOLID PRODRUGS
ES2151508T3 (es) Empleo de inhibidores de reductasa 3-hidroxi-3-metilglutaril coenzima a como una modalidad en la terapia del cancer.
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
IL114382A0 (en) Cancer therapy using lymphotoxin
ATE267599T1 (de) Verwendung von chelerythrin und strahlung in der tumortherapie
PT980205E (pt) Utilizacao da combinacao de celulas tall-104 com adriamicina ou cisplatina na terapia de tumores malignos
WO2001034131A3 (en) Combination chemotherapy
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
MXPA03003798A (es) Derivados triciclicos de indol con actividad antiangiogenica.
CA2243392A1 (en) Use of a texaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
PT930877E (pt) D-metionina para reduzir a toxicidade de compostos antitumorais contendo platina
PT1135161E (pt) Composicao e metodo terapeutico
UA33359A (uk) Спосіб доступу до пухлин орбіти

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application